순환종양세포(CTC) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global circulating tumor cells market size is expected to reach USD 49.39 Billion in 2034 from USD 15.31 Billion in 2025, growing at a CAGR of 13.9% during 2026-2034.This market is gaining importance as researchers and healthcare professionals investigate circulating tumor cells as potential sources of information about cancer progression and treatment response. Circulating tumor cells are cancer cells that detach from tumors and enter the bloodstream. Their detection and analysis may provide insights into tumor characteristics without requiring repeated tissue sampling in certain research or clinical settings. Growing interest in liquid biopsy, precision oncology, and minimally invasive monitoring is encouraging the development of technologies that isolate and characterize these rare cells. However, their clinical usefulness depends on the cancer type, testing method, and intended application.

Market growth is driven by advances in cancer research, improvements in cell isolation technologies, and increasing investment in liquid biopsy platforms. Researchers are developing methods that use physical properties, cell-surface markers, imaging, and molecular analysis to identify circulating tumor cells among large numbers of blood cells. Diagnostic technology companies and research institutions are exploring applications in treatment monitoring, prognosis assessment, and investigation of metastatic disease. Improvements in microfluidics, automated imaging, and single-cell analysis are also supporting more detailed characterization. Collaborations between biotechnology companies and oncology research centers are helping advance technical development and clinical evaluation.

The future prospects of this market will depend on stronger clinical validation, improved detection sensitivity, and the development of standardized testing methods. Advances in single-cell sequencing and molecular profiling could provide more detailed information about tumor heterogeneity and potential treatment resistance. Integration with other liquid biopsy approaches may help researchers build a more comprehensive picture of cancer progression. However, low cell counts, variation between tumors, technical complexity, and the need for reproducible results remain significant challenges. Broader adoption will require clear evidence that circulating tumor cell analysis improves clinical decisions or patient management in defined settings.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Kits & Reagents
• Blood Collection Tubes
• Devices

By Technology

• CTC Detection & Enrichment Methods
• CTC Direct Detection
• CTC Analysis

By Application

• Research, Clinical
• Drug/Therapy Development

By Specimen

• Blood
• Bone Marrow
• Other Body Fluids

By End User

• Hospital and Clinics
• Diagnostic Centers
• Research and Academic Institutes

COMPANIES PROFILED

• Menarini Silicon Biosystems, Bio-Rad Laboratories, QIAGEN, Thermo Fisher Scientific, Roche, Epic Sciences, RareCyte, Biocept, ScreenCell, Celsee, ANGLE, Ikonisys, CytoTrack, ApoCell, Canopus Bioscience, Creatv MicroTech, AdnaGen, Sysmex, STEMCELL Technologies, Miltenyi Biotec

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CIRCULATING TUMOR CELLS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Kits & Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Blood Collection Tubes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CIRCULATING TUMOR CELLS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. CTC Detection & Enrichment Methods Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. CTC Direct Detection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. CTC Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CIRCULATING TUMOR CELLS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Research, Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Drug/Therapy Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CIRCULATING TUMOR CELLS MARKET: BY SPECIMEN 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Specimen
• 7.2. Blood Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Bone Marrow Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Other Body Fluids Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CIRCULATING TUMOR CELLS MARKET: BY END USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End User
• 8.2. Hospital and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Research and Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CIRCULATING TUMOR CELLS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product
  • 9.2.2 By Technology
  • 9.2.3 By Application
  • 9.2.4 By Specimen
  • 9.2.5 By End User
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product
  • 9.3.2 By Technology
  • 9.3.3 By Application
  • 9.3.4 By Specimen
  • 9.3.5 By End User
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Spain
  • 9.3.11 Russia
  • 9.3.12 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product
  • 9.4.2 By Technology
  • 9.4.3 By Application
  • 9.4.4 By Specimen
  • 9.4.5 By End User
  • 9.4.6 China
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 India
  • 9.4.10 Australia
  • 9.4.11 South East Asia
  • 9.4.12 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product
  • 9.5.2 By Technology
  • 9.5.3 By Application
  • 9.5.4 By Specimen
  • 9.5.5 By End User
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product
  • 9.6.2 By Technology
  • 9.6.3 By Application
  • 9.6.4 By Specimen
  • 9.6.5 By End User
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL CIRCULATING TUMOR CELLS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Menarini Silicon Biosystems
  • 11.2.2 Bio-Rad Laboratories
  • 11.2.3 QIAGEN
  • 11.2.4 Thermo Fisher Scientific
  • 11.2.5 Roche
  • 11.2.6 Epic Sciences
  • 11.2.7 RareCyte
  • 11.2.8 Biocept
  • 11.2.9 ScreenCell
  • 11.2.10 Celsee
  • 11.2.11 ANGLE
  • 11.2.12 Ikonisys
  • 11.2.13 CytoTrack
  • 11.2.14 ApoCell
  • 11.2.15 Canopus Bioscience
  • 11.2.16 Creatv MicroTech
  • 11.2.17 AdnaGen
  • 11.2.18 Sysmex
  • 11.2.19 STEMCELL Technologies
  • 11.2.20 Miltenyi Biotec